(Oslo, 21st of November 2019) Medistim ASA (OSE: MEDI), a niche market leader
within ultrasound technology with headquarter in Norway, that develops and
commercializes medical equipment for use within cardiac, vascular and transplant
surgery, announces that they have received confirmation from Canadian health
authorities, Health Canada, that its newest product MiraQ is approved for sale
in the Canadian market. 

MiraQ is Medistim's newest generation of product for quality assurance within
vascular and cardiac surgery. The system is based on ultrasound, and combines
quantitative blood flow measurement through transit time flow measurement (TTFM)
and high frequency ultrasound imaging (HFUS).  Medistim's unique TTFM and HFUS
combination provides guidance and control during surgery, in order to avoid or
correct issues intraoperatively.
Medistim is now in position to sell MiraQ in all markets. This means that the
previous generation, the VeriQTM, is no longer in production and sale.

Canada is a substantial market for Medistim with about 30 hospitals performing
on average 18 000 cardiac procedures per year. Medistim's equipment is used in
about 37 % of the procedures. It is expected that a large portion of existing
users over time will convert to  the new product MiraQ. Medistim's products are
well accepted in the Canadian market and the company is also optimistic with
regard to sales of MiraQ to new customers . Medistim is well represented in the
Canadian market through its distributor Medtronic.

About Medistim:
Medistim was established in 1984, and has a track record of profitable growth
over the past >15 years.  The company is a pioneer within its segment, and
continues to invest in new product development.  Medistim has wholly owned
subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark
and Norway, in addition to the about 50 distributors in Europe, Asia, Middle
East, Africa, Canada and South America.   For more information, visit the
Medistim home page:  www.Medistim.com 
This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12).
For more information, contact: 

President and CEO, Kari E. Krogstad, Medistim ASA 
Tel: + 47 918 38 110  
Email: kari.krogstad@medistim.com 
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940  
Email: thomas.jakobsen@medistim.com

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange